ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / TELA / dividends
CVRX (31) NEPH (59) XTNT (65) DAVI (47) ⌘ Pro Terminal β†’

TELA Bio Inc. (TELA) Dividend Safety Gauge & 10-Year DRIP Compounder

$0.80 -1.33% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.80

TELA Bio Inc. (TELA) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $36.6M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TELA Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is TELA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, TELA Bio Inc. (NASDAQ: TELA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.80 (-1.33% 1D, market cap $36.6M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 9/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, TELA ranks #603 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does TELA compare to CVRX and NEPH in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Dental Instruments), TELA carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 67.7%, and ROIC of -35.0%. By comparison, CVRX (CVRx Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $37.6M) and NEPH (Nephros Inc.) posts a C- grade (59/100 RQD, P/E 29.8x, ROIC 18.9%, cap $34.5M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TELA?
β–Ό

Per TELA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001561921), TELA Bio Inc. generated $80.3M in revenue (+15.8% YoY), -$38.8M in net income, and -$28.7M in free cash flow against $81.4M in total assets and $55.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.80 (-0.43%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 9/20 (D) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (35/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510035
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- Β· Rk E
Cash (9)Whales (8)SEC (9)Macro (4)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10% Base Target
$2 Bull$1 Base$1 Bear
πŸ“¬ FREE TELA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for TELA)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
πŸ” WHY TELA SCORES 35/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Cash Engine Quality+9/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 67.7% Gross Margin

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+9/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 4/9

β–Ό #1 Drag / Risk Factor: Macro Regime Fit4/20 pts (-16 pt drag)

Macro rate sensitivity & RSI-14 (37.6) create a -16 pt regime headwind

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
43
Grade D$1.07+1.9% Next Q
Q2 (-2Q)
40
Grade D$1.09-11.9% Next Q
Q3 (-1Q)
38
Grade E$0.96-16.7% Next Q
Current
35
Grade D-$0.80-8.5% Hist 90D Ξ±
Trajectory: D (43) β†’ D- (35)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a TELA Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While TELA currently carries a cautious 35/100 (D-) rating due to Macro Regime Fit (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.02) and Max Pain ($0.84) forces dealer call-delta covering toward $1.58.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TELAβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œTELA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 35%NO 65%Trade / Inspect Odds β†’
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 β€’ REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (10.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years β†’ $27,141

Est. Year-10 Shareholder Yield: $489/yr
$11.1K
Yr 1
$12.2K
Yr 2
$13.5K
Yr 3
$14.9K
Yr 4
$16.5K
Yr 5
$18.2K
Yr 6
$20.1K
Yr 7
$22.2K
Yr 8
$24.6K
Yr 9
$27.1K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TELA)

  • βœ“Walkthrough of TELA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
TELA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.61%πŸ“ HORIZONTAL RANGE
2026-11-03O $0.92H $0.92L $0.80C $0.80VOL 330.1K
RES: $1.70SUP: $0.50SMA50: $1.02SMA200: $0.86
$1.56$1.30$1.04$0.78$0.52RES $1.70SUP $0.50$0.802026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TELA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ TELA Butterfly Map β†’ + Track TELA β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +15.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on TELA today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for TELA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TELA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TELA)

Health Care Rank #603 of 1015 βš”οΈ CVRX vs TELA Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (TELA vs. CVRX, NEPH, XTNT, DAVI)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, TELA Bio Inc. (TELA) ranks #603 by composite RQD confidence (35/100, grade D-) and #778 by equity capitalization ($36.6M). Within this direct 5-issuer industry benchmark cohort, NEPH leads on earnings valuation at 29.8x trailing P/E, while NEPH leads on capital efficiency and profitability with 18.9% ROIC and 61.9% gross margin. XTNT currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with TELA at 35/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
TELA ACTIVE
TELA Bio Inc.
D- 35/100 β€” 67.7% -35.0% -1.33% $36.6M Benchmark Subject
CVRX
CVRx Inc.
E 31/100 β€” 85.3% -35.0% -2.84% $37.6M /cvrx-vs-tela β†’
NEPH
Nephros Inc.
C- 59/100 29.8x 61.9% 18.9% +2.21% $34.5M /neph-vs-tela β†’
XTNT
Xtant Medical Holdings Inc.
C 65/100 β€” 62.9% 12.8% -0.64% $39.3M /xtnt-vs-tela β†’
DAVI
Davion Healthcare Plc
D 47/100 β€” β€” β€” -11.31% $42.0M /davi-vs-tela β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001561921 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), TELA Bio Inc. (TELA) reported GAAP revenue of $80.3M (+15.8% vs. FY2024 revenue of $69.3M , and +37.3% cumulative change since FY2023) , GAAP net income of -$38.8M, operating cash flow of -$28.2M, and free cash flow of -$28.7M (+32.7% YoY). On the balance sheet, TELA closed FY2025 with $81.4M in total assets against $55.7M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $80.3M -$38.8M -$28.2M -$28.7M $81.4M $55.7M
FY2024 (FY) 2024-12-31 $69.3M -$37.8M -$41.6M -$42.6M $86.6M $41.1M
FY2023 (FY) 2023-12-31 $58.5M -$46.7M -$40.9M -$40.9M β€” β€”

3. TELA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TELA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, TELA Bio Inc. (NASDAQ: TELA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.80 (-1.33% 1D, market cap $36.6M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 9/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, TELA ranks #603 in composite RQD confidence.

How does TELA compare to CVRX and NEPH in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), TELA carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 67.7%, and ROIC of -35.0%. By comparison, CVRX (CVRx Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $37.6M) and NEPH (Nephros Inc.) posts a C- grade (59/100 RQD, P/E 29.8x, ROIC 18.9%, cap $34.5M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TELA?

Per TELA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001561921), TELA Bio Inc. generated $80.3M in revenue (+15.8% YoY), -$38.8M in net income, and -$28.7M in free cash flow against $81.4M in total assets and $55.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TELA trading relative to its 50-day, 200-day, and 52-week technical levels?

TELA last traded at $0.80 (-1.33% on volume of 165,257 shares), positioning the stock -21.57% below its 50-day simple moving average ($1.02) and -6.98% below its 200-day simple moving average ($0.86). Across its 52-week range of $0.50 to $1.50, TELA sits at the 30.0% percentile with a 14-day RSI of 37.6 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.00 to $0.90).

Direct Sub-Reports: TELA RQD Cockpit TELA 12M Forecast TELA Earnings & Move TELA Dividends & DRIP TELA Insiders & 13F TELA Whale Options TELA Profit Sankey TELA News & Why
ROARABLE RATING BRIEF β€’ RQD 35/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

TELA β€” TELA Bio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

TELA Bio Inc. (TELA) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.80 (-1.33% 1D, market capitalization $36.6M).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 67.7%, operating margin of -42.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (4/20) + Forensic Balance Sheet (9/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of 8.50x.

2. Business Model, Unit Margins & SEC Financial Trajectory

TELA Bio Inc. Is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry. Its market capitalization is $0.0B. Per the news wire, the company has received FDA 510(k) clearance for its Liora Monofilament Scaffold, described as a soft-tissue reinforcement product, which suggests its product line centers on surgical implant-type devices. Revenue figures are reported in the financials section.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), TELA Bio Inc. (TELA) reported $80.3M in annual revenue (up from $69.3M in FY2024, +15.8% YoY) and -$38.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($58.5M revenue, -$46.7M net income) through FY2025, TELA scaled operating cash flow to -$28.2M and free cash flow to -$28.7M, backed by $81.4M in total assets against $55.7M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 8/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $0.50 – $1.50 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -42.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

A prospective investor should note that the absence of mapped dependencies is itself a gap: the company's reliance on specific component suppliers, surgical-channel customers, or reimbursement pathways cannot be assessed from these sources. The only sector-level context available is the Health Care / Medical-Dental Instruments classification and the beta of 1.0.

  • Key Question #1: Can TELA sustain or expand its -42.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $80.3M and free cash flow of -$28.7M, how will capital allocation balance growth reinvestment against $55.7M in total debt?
  • Key Question #3: How sensitive is TELA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

TELA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for TELA Bio Inc. (TELA) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to TELA Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TELA Bull vs. Bear Conversation Board β€” What's Your Call at $0.80?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TELA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on TELA:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER β€’ Price Action & Volume Trader πŸ‚ BULLISH 🎯 Target: $1.00 (+23.5%)
πŸ“Œ Pinned Debate

FDA 510(k) clearance for the Liora Monofilament Scaffold gives the company a fresh regulatory catalyst to support revenue growth from $

Here is why I am bullish on TELA here at $0.81: FDA 510(k) clearance for the Liora Monofilament Scaffold gives the company a fresh regulatory catalyst to support revenue growth from $58.5M to $80.3M over FY 2023–FY 2025.. Compare TELA's -42.0% operating margin and -35.0% ROIC against the rest of Medical/Dental Instruments. As long as cash conversion holds up, dips toward $0.77 are getting bought.

EarningsSniper πŸ‚ BULL

@SkepticalCFA Shorting a 8/20 institutional whale-flow stock at $0.81 is dangerous when funds are rotating into Health Care.

SK SkepticalCFA RQD DEBATE OPENER β€’ Fundamental Contrarian 🐻 BEARISH 🎯 Target: $0.62 (-23.5%)
Spot @ $0.81

With FY 2025 free cash flow of -$28.7M, debt rising to $55.7M against $50.8M of cash, and a Piotroski F-Score of 4/9, the balance sheet

Sitting on the sidelines or leaning short TELA above $0.81. With FY 2025 free cash flow of -$28.7M, debt rising to $55.7M against $50.8M of cash, and a Piotroski F-Score of 4/9, the balance sheet is under visible pressure.. Until Fundamental Cash Engine (9/20) and FCF yield (0.0%) inflect higher, upside is capped near $1.50.

LIVE TAPE